Somatropin biosimilar - AryaTinaGene
Latest Information Update: 26 Jul 2022
At a glance
- Originator AryaTinaGene Biopharmaceuticals
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Somatotropin deficiency
Most Recent Events
- 26 Jul 2022 Somatropin biosimilar is still in phase III trials for Somatotropin deficiency (In children) in Iran (SC) (IRCT20171122037571N1)
- 11 Nov 2021 AryaTinaGene Biopharmaceuticals completes enrolment in its phase III trial for Somatotropin deficiency (In children) in Iran (SC) (IRCT20171122037571N1)
- 05 May 2019 Phase-III clinical trials in Somatotropin deficiency (In children) in Iran (SC)